Article Text

AB0173 Metabolomics in Primary SjÖgren's Syndrome: Data from the Assess Cohort
  1. J.E. Gottenberg1,
  2. F. Moussalieh2,
  3. R. Seror3,
  4. P. Ravaud4,
  5. J. Benessiano5,
  6. P. Dieude6,
  7. E. Dernis7,
  8. V. Devauchelle-Pensec8,
  9. J.J. Dubost9,
  10. A.L. Fauchais10,
  11. V. Goeb11,
  12. E. Hachulla12,
  13. J. Morel13,
  14. P.Y. Hatron12,
  15. C. Larroche14,
  16. V. Le Guern15,
  17. J. Morel13,
  18. A. Perdriger16,
  19. X. Puéchal15,
  20. S. Rist17,
  21. A. Saraux18,
  22. D. Sene19,
  23. J. Sibilia20,
  24. O. Vittecoq21,
  25. P. Ravaud22,
  26. K. Elbayed2,
  27. X. Mariette3,
  28. I. Namer2
  1. 1Rheumatology
  2. 2Nuclear Medicine, Strasbourg University Hospital, Strasbourg
  3. 3Rheumatology, Bicêtre Hospital
  4. 4Clinical epidemiology, Hôtel-Dieu Hospital
  5. 5Biology
  6. 6Rheumatologie, Bichat Hospital, Paris
  7. 7Rheumatology, University Hospital, LEMANS
  8. 8Rheumatologie, University Hospital, Brest
  9. 9Rheumatology, University Hospital, Clermont-Ferrand
  10. 10Internal Medicine, University Hospital, Limoges
  11. 11Rheumatology, University Hospital, Amiens
  12. 12Internal Medicine, University Hospital, Lille
  13. 13Rheumatology, University Hospital, Montpellier
  14. 14Internal Medicine, Avicenne Hospital
  15. 15Internal Medicine, Cochin Hospital, Paris
  16. 16Rheumatology, University Hospital, Rennes
  17. 17Rheumatology, University Hospital, Orléans
  18. 18Rheumatology, University Hospital, Brest
  19. 19Internal Medicine, Lariboisière Hospital, Paris
  20. 20Rheumatology, University Hospital, Strasbourg
  21. 21Rheumatologie, University Hospital, Rouen
  22. 22Epidemiology center, Hôtel Dieu Hospital, Paris, France


Background High throughput study of metabolic pathways might help identify new biomarkers and therapeutic targets in autoimmune diseases. Primary Sjögren's syndrome (pSS) currently lacks prognostic biomarkers and efficacious and specific treatments. We therefore assessed serum levels of 35 metabolites in pSS using high-resolution magic-angle spinning (HRMAS) proton magnetic resonance spectroscopy.

Methods The blood samples of 194 patients with pSS enrolled in the prospective multicenter ASSESS cohort and 41 blood donors were analysed in this study. After cryopreservation at -80°C, the samples were studied with HRMAS proton magnetic resonance spectroscopy (1H-MRS). Spectra were recorded on a Bruker Avance III 500 spectrometer operating at a proton frequency of 500 MHz. All the 1D NMR spectra were acquired during 76 min. Supervised clustering was performed on the spectral region between 0.5 and 4.7 ppm using partial least square discriminant analysis (PLS-DA).

Results Supervised clustering of the 194 samples allowed to discriminate all patients with pSS from healthy controls (R2Y=0.88 and Q2=0.86 (figure 1)). Interestingly, 4 serum metabolites were significantly increased in pSS compared to healthy controls: threonine, lactate, glutamine and acetate. 6 metabolites were significantly decreased in pSS compared to healthy controls: myo-inositol, creatine, lysine, aspartate, glutamate and alanine

Conclusions This first high-throughput analysis of metabolic pathways disclosed a specific metabolomic signature of pSS allowing discriminating all patients with pSS from controls. This new and very potent means of metabolic analysis may help to increase our knowledge on the pathogenesis of pSS, identify biomarkers, and new therapeutic targets.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.